Sodium Valproate: Compensation
The question
To ask the Secretary of State for Health and Social Care, for what reason recommendations for a sodium valproate redress scheme have not been implemented.
Answered by Dr Zubir Ahmed
The Department continues to take forward work to explore redress for those affected by pelvic mesh and sodium valproate, which includes recommendations made by the Patient Safety Commissioner in the Hughes Report. We recognise the importance of these issues for all those affected. This remains a cross-Government policy area involving multiple organisations, and given the complexity of the issues involved, it is important we get this right.
I met with the Patient Safety Commissioner in December 2025, to discuss progress following the Hughes Report and have made clear the Department’s expectation of continued, proactive engagement with the Patient Safety Commissioner and key stakeholders. I have also written to the Patient Safety Commissioner regarding further steps to be taken to improve the lives of those affected by valproate and mesh. A copy of that letter is attached.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →